Shots:

• Regor to receive ~$50M up front including an equity investment & is also eligible to receive ~$1.5B based on the achievement of prespecified preclinical, clinical development, and commercial milestones along with royalties resulting from the collaboration
• Lilly get a license to select Regor intellectual property with an option to extend the license & will lead the clinical development, manufacturing, and commercialization globally Ex- China, Macau, Hong Kong, and Taiwan where Regor will maintain the rights & responsibilities
• The agreement leverages Regor's technology to accelerate the breakthrough  therapies for the treatment of obesity and diabetes

Ref: Lilly | Image: Lilly